Tumor Monitoring
Tumor Monitoring - Related Videos
06:26
PTM Based Tumor Microenvironment Monitoring: A Method for Tracking Changes in ECM Rigidity Using Tumor Spheroids
0 Views •
2023
This protocol describes a technique for monitoring extracellular matrix rigidity changes by using particle-tracking microrheology (PTM). This is done by culturing 3D pancreatic tumor spheroids into ECM with embedded fluorescent probes for video particle-tracking and analysis.
03:07
Morphological and Physiological Monitoring of Tumor Spheroids Using Optical Coherence Tomography
0 Views •
2025
Source: Huang, Y. et. al., Longitudinal Morphological and Physiological Monitoring of Three-dimensional Tumor Spheroids Using Optical Coherence Tomography. J. Vis. Exp. (2019)This video demonstrates the use of optical coherence tomography (OCT) to monitor tumor spheroids in a multi-well plate by capturing high-resolution cross-sectional images. By analyzing light reflections from cellular structures, OCT constructs 3D models to assess morphological features like size and shape while also...
10:35
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
0 Views •
Cited by 18 •
2010
To study in vivo tumor growth and tumor microenvironment, we used a syngeneic and orthotopic mouse model of ovarian cancer in immunocompetent animals. We transduced a mouse tumor cell line (MOV1) with Katushka fluorescent protein (MOV1KAT) and here we show its orthotopic implantation in ovary and in vivo imaging.
07:12
Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models
0 Views •
Cited by 29 •
2016
Bioluminescence imaging is a well-known tool for localizing tumors and metastases, but quantification of these images often requires complex calculations and particular instruments. We describe the easy-to-use luminoscore method, based on precise acquisition conditions, requiring no calculations, and enabling tumor burden and treatment response to be monitored in mouse models.
06:53
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
0 Views •
Cited by 7 •
2019
Here, we present a protocol to detect tumor somatic mutations in circulating DNA present in patient biological fluids (biofluids). Our droplet digital polymerase chain reaction (dPCR)-based method enables quantification of the tumor mutation allelic frequency (MAF), facilitating a minimally invasive complement to diagnosis and temporal monitoring of tumor response.
FAQs
Different monitoring tools capture different aspects of tumor status. Medical imaging and physical examination can contribute information about visible or clinically assessed changes, while biopsy provides tissue-based evidence. Circulating and molecular biomarkers add signals about tumor biology. Using these sources together can help distinguish a change in tumor burden from a change in biological activity, supporting a more complete interpretation of treatment response.
These categories are interpreted as longitudinal patterns rather than isolated labels. A tumor may shrink, remain unchanged, enlarge, or reappear after treatment, while treatment-related effects can also alter findings. Comparing results from repeated assessments helps researchers and clinicians determine whether an observed change is consistent with response, stability, progression, or recurrence and whether management may need reconsideration.
Repeated assessments provide a time-based view that a single observation cannot. Tracking tumor size, presence, activity, response, or molecular signals can show the direction of change and reveal whether treatment effects persist or evolve. This longitudinal perspective supports therapy selection, treatment adjustment, and evaluation of outcomes in cancer research.
A tumor monitoring process consists of repeated assessments of relevant tumor features during or after treatment. Imaging, examination, biopsy, and circulating or molecular biomarkers may be combined rather than used identically for every assessment. Results are compared across time to evaluate tumor burden, biology, response, and treatment-related effects.
Circulating and molecular biomarkers can add biological information that is not captured by tumor size alone. When interpreted alongside imaging, physical examination, or tissue biopsy, these measurements may help characterize changes in tumor biology and treatment response. Their value in a monitoring program comes from comparing biomarker findings over time with other evidence of tumor burden or activity.
In cancer research, tumor monitoring supports more than routine follow-up. Longitudinal measurements can help investigators evaluate clinical trial outcomes, compare how tumors respond during treatment, and identify information relevant to therapy selection or adjustment. The same approach also contributes to personalized patient management by linking observed changes in tumor burden or biology with decisions made over the course of care.